An HIV-tailored quit-smoking counselling pilot intervention targeting depressive symptoms plus Nicotine Replacement Therapy

Datos Bibliográficos

ID19440650
AutoresLouise Balfour (0000-0002-7088-3924, University of Ottawa), Stephanie A Wiebe (0000-0001-5865-4531, University of Ottawa, autor de correspondencia), D William Cameron (0000-0002-0090-3539, University of Ottawa), William D Cameron, Daniella Sandre (University of Ottawa), Andrew Pipe (0000-0003-1280-1801, University of Ottawa), Curtis Cooper (0000-0002-3368-3499, University of Ottawa), Jonathan B Angel (0000-0003-3102-4462, University of Ottawa), Jonathan Angel, Gary Garber (0000-0001-7633-5630, University of Ottawa), Crystal Holly (University of Ottawa), Tracy L Dalgleish (Ottawa Public Health), Giorgio A Tasca (0000-0001-7596-0661, University of Ottawa), Paul A Macpherson, Paul Macpherson (0000-0001-7348-6775, University of Ottawa)
Año2017
Volumen29
Número1
Páginas24-31
Fecha de publicación2017-01-02
Peer ReviewedSí
Open AccessNo
TipoARTICLE
RevistaAIDS Care (JOURNAL)
Identificadores de la revistaISSN: 0954-0121 • E-ISSN: 1360-0451
EditorialInforma UK Limited (PUBLISHER • GB)
DOI10.1080/09540121.2016.1201195
PMID27435835
OpenAlexW2501702310
IdiomaEN
Citas recibidas1
Referencias citadas35

Cardiovascular disease (CVD) rates among people living with HIV/AIDS (PHAs) are high. Rates of cigarette smoking, a leading contributor to CVD among PHAs, are 40-70% (2-3 times higher than the general population). Furthermore, PHAs have high rates of depression (40-60%), a risk factor for smoking cessation relapse. The current pilot study examined the effectiveness of a specifically tailored 5-session smoking cessation counselling programme for PHAs, which addressed depression, in combination with Nicotine Replacement Therapy (NRT) in a cohort of PHA smokers (n = 50). At 6-month follow-up, 28% of participants demonstrated biochemically verified abstinence from smoking. This result compares favourably to other quit-smoking intervention studies, particularly given the high percentage of HIV+ smokers with depression. At study baseline, 52% of HIV+ smokers scored above the clinical cut-off for depression on the Centre for Epidemiological Studies - Depression (CES-D) scale. HIV+ smokers with depression at study baseline demonstrated quantitatively lower depression at 6-month follow-up with a large effect size (d = 1), though it did not reach statistical significance (p = .058). Furthermore, those with depression were no more likely to relapse than those without depression (p = .33), suggesting that our counselling programme adequately addressed this significant barrier to smoking cessation among PHAs. Our pilot study indicates the importance of tailored programmes to help PHAs quit smoking, the significance of addressing depressive symptoms, and the need for tailored counselling programmes to enhance quit rates among PHAs

Anxiety · Depressive symptoms · Family medicine · Nicotine · Nicotine replacement therapy · Psychiatry · Quit smoking · Smoking cessation · Eating Disorders and Behaviors · Medicine · Smoking Behavior and Cessation